Explore

Trendline Trendline
Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development

Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development

Enveric Biosciences Reports First Quarter 2026 Financial Results and Advances Drug Development
Reuters Reuters
Trump's psychedelic drug order boosts investor interest with promise of faster reviews

Trump's psychedelic drug order boosts investor interest with promise of faster reviews

By Kamal Choudhury and Christy Santhosh May 18 (Reuters) - U.S.
Trendline Trendline
Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase

Northwest Biotherapeutics Reports Q1 2026 Financial Results with Revenue Increase
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss
Trendline Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue

Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials

Inhibrx Biosciences Reports Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
CervoMed Faces Financial Challenges Amid Clinical Advancements

CervoMed Faces Financial Challenges Amid Clinical Advancements

CervoMed Faces Financial Challenges Amid Clinical Advancements
Trendline Trendline
Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026

Inhibrx Reports Financial Results and Clinical Trial Updates for Q1 2026
Trendline Trendline
Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses

Marker Therapeutics Reports Q1 2026 Financial Results with Reduced Losses
Trendline Trendline
Alpha Cognition Reports Strong Q1 2026 Financial Results and Operational Progress

Alpha Cognition Reports Strong Q1 2026 Financial Results and Operational Progress

Alpha Cognition Reports Strong Q1 2026 Financial Results and Operational Progress
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements